Biohaven Misses The Mark In Depression Trial, Stock Falls - Biohaven (NYSE:BHVN)

Biohaven Misses The Mark In Depression Trial, Stock Falls - Biohaven (NYSE:BHVN)

On Wednesday, Biohaven Ltd. (NYSE:BHVN) reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for major depressive disorder (MDD). The study did not meet its primary endpoint, a reduction of depressive symptoms as measured by change in the Montgomery Åsberg Depression Rating Scale (MADRS) over six weeks compared with placebo. Trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants…

Biohaven’s ion channel drug fails again, this time in major depressive disorder

Biohaven said its potassium channel drug failed a Phase 2 trial in patients with major depressive disorder, the second mid-stage setback for its experimental treatment. The Connecticut ...

Biohaven reports Phase II BHV-7000 trial results for MDD

Biohaven has announced findings from its Phase II proof-of-concept trial of BHV-7000 in adults with MDD, focusing on the reduction of depressive symptoms as measured by the MADRS over six weeks.The post Biohaven reports Phase II BHV-7000 trial results for MDD appeared first on Clinical Trials Arena.